AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2016
Dec 6, 2016
33422_dirs_2016-12-06_b76b5134-5da3-41e8-8453-89796509348b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2016-12-03
Reporting Person: TRABER PETER G (Director, President & CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-12-03 | Stock option (right to buy) | $.87 | A | 220000 | Acquired | 2026-12-03 | Common Stock (220000) | Direct |
Footnotes
F1: The options vest as follows: 25% immediately, 25% on July 1, 2017, and 50% on December 31, 2017.
More from GALECTIN THERAPEUTICS INC
Earnings Release
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Mar 31
Earnings Release
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Mar 17
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 21